The further blockage of IGF activity by elevated IGFBP-2 levels in SIRS/sepsis—as shown in our study—might intensify these catabolic processes, leading to sarcopenia and cachexia. This evidence concerns the gene IGFBP2 and systemic inflammatory response syndrome.